How should the front-line clinician treating T2D patients translate the results of the LEADER trial into clinical practice? Have these results prioritized GLP-1 RAs in the T2D treatment pathway?

How should the front-line clinician treating T2D patients translate the results of the LEADER trial into clinical practice? Have these results prioritized GLP-1 RAs in the T2D treatment pathway?

How should the front-line clinician treating T2D patients translate the results of the LEADER trial into clinical practice? Have these results prioritized GLP-1 RAs in the T2D treatment pathway?


Created by

CMEducation Resources IQ&A Interactive Intelligence Zone

Presenter

Ralph DeFronzo, MD

Ralph DeFronzo, MD

Professor of Medicine
Chief of the Diabetes Division
The University of Texas Health Science Center at San Antonio
San Antonio, Texas